Accessibility Menu
Scholar Rock logo

Scholar Rock(NASDAQ) SRRK

Current Price$49.48
Market Cap$5.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+212%
5 Year+52%
1 Year+25%
1 Month-3%
Scholar Rock last closing stock price
MetricPriceDate
Last closeUSD 49.482026-07-23
Scholar Rock stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.35%USD 51.732026-07-16
1 month-3.49%USD 51.272026-06-23
3 month+6.45%USD 46.482026-04-24
Year to date+12.33%USD 44.052025-12-31
1 year+24.6%USD 39.712025-07-23
3 year+629.79%USD 6.782023-07-24
5 year+51.55%USD 32.652021-07-23
Since inception+211.61%USD 15.502018-05-24

Scholar Rock Financials at a Glance

Market Cap

$5.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$408.73M

EPS (TTM)

-$3.59

P/E Ratio

-13.47

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Price

$49.48

Volume

29,502

Open

$47.58

Previous Close

$49.48

Daily Range

$47.58 - $49.63

52-Week Range

$27.07 - $58.49

Estimated Earnings Date

Aug 6, 2026

SRRK News

BuyAlert-Blue.png

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%

Jonathan PoncianoFeb 22, 2026
SellAlert-Purple.png

Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026

Adé HennisFeb 1, 2026
SellAlert-Red.png

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away

Jonathan PoncianoDec 3, 2025
Person checking medicine on a shelf in a pharmacy

Why Scholar Rock Stock Got Socked on Monday

Eric VolkmanOct 13, 2025
Person in a lab gazing into a microscope

Why Scholar Rock Stock Raced 6% Higher Today

Eric VolkmanOct 9, 2025
Person in a lab gazing into a microscope

Why Scholar Rock Stock Bounced Higher on Monday

Eric VolkmanSep 15, 2025
Two people in white lab coats looking at a computer display

Why Scholar Rock Stock Wilted on Wednesday

Eric VolkmanAug 6, 2025
Foolcom-Featured.png

Scholar Rock (SRRK) Q2 Loss Widens 63%

Motley Fool Markets TeamAug 6, 2025
Page 1

SRRK: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scholar Rock

Scholar Rock develops medicines for people with serious muscle and nerve diseases. Its main drug helps those with spinal muscular atrophy, a rare muscle-weakening condition. The company also works on treatments for cancer and tissue scarring disorders.

Products and Services

  • Apitegromab (SMA therapy): Antibody drug for spinal muscular atrophy; no product revenue yet.
  • SRK-181 (Cancer therapy): Experimental antibody for cancers resistant to standard immunotherapies; no product revenue yet.
  • SRK-439 (Neuromuscular disorders): Preclinical antibody for muscle diseases and obesity; no product revenue yet.
  • SRK-373 (Fibrosis therapy): Early-stage drug for tissue scarring diseases; no product revenue yet.
  • Research collaborations: Partnership with Gilead Sciences for fibrosis drug discovery; minor research revenue only.

Growth and Expansion

  • 2018: Listed on NASDAQ Global Select Market.
  • 2020–2025: Advanced apitegromab through Phase 3 trials for spinal muscular atrophy.
  • 2021: Entered collaboration with Gilead Sciences for fibrosis drug research.
  • 2025: Submitted apitegromab for regulatory review in the US and Europe.
  • 2025: Launched new clinical programs for obesity and neuromuscular disorders.

What Makes Scholar Rock Stand Out

Scholar Rock uses a unique approach to target inactive forms of disease-causing proteins, aiming to reduce side effects. Its focus on rare muscle and nerve diseases sets it apart from broader drug companies. The company relies on partnerships and a specialized research platform to advance its pipeline.

Five Things You Need to Know

  • No product revenue as of Q2 2025; all income from research collaborations.
  • Net loss was $110 million in Q2 2025, up 88.1% from Q2 2024.
  • Operating expenses rose to $112 million in Q2 2025, up 88.4% year-over-year.
  • Cash and marketable securities totaled $295 million as of June 30, 2025.
  • 128 full-time employees as of June 2025; company expects to need more capital for growth.

Bottom Line

Scholar Rock is a late-stage biotech focused on rare muscle and nerve diseases. The company is expanding its pipeline but remains pre-revenue, with high research costs and ongoing need for funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

289

CEO

David L. Hallal

Website

www.scholarrock.com

Headquarters

Cambridge, MA 02142, US

SRRK Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-163.52%

Return on Capital

-108.53%

Return on Assets

-76.36%

Earnings Yield

-7.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

119.83M

Volume

29.50K

Avg. Volume

1.40M

Financials (TTM)

Gross Profit

-$98.11M

Operating Income

-$409.57M

EBITDA

-$399.75M

Operating Cash Flow

-$303.46M

Capital Expenditure

-$399.00K

Free Cash Flow

-$303.86M

Cash & ST Invst.

$479.94M

Total Debt

$205.67M

Scholar Rock Performance Analysis

Scholar Rock annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 33,193,00076.4%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Scholar Rock sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Scholar Rock annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.26-37.2%
20232023-12-31USD -1.99-11.8%
20242024-12-31USD -2.4724.0%
20252025-12-31USD -3.3033.6%
Scholar Rock sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-46.3%
Q32025-09-308.2%
Q42025-12-3117.8%
Q12026-03-31-12.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$335.00K

+99.3%

Gross Margin

0.00%

N/A

Market Cap

$5.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.03M

N/A

Employees

289

N/A

Net Income

-$105.51M

-41.2%

EBITDA

-$102.87M

-38.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$479.94M

+31.7%

Total Debt

$205.67M

+225.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$199.60M

+246.2%

Short Term Debt

$6.08M

+10.5%

Return on Assets

-76.36%

N/A

Return on Invested Capital

-86.11%

N/A

Free Cash Flow

-$82.17M

-4.1%

Operating Cash Flow

-$82.10M

-4.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CDTXCidara Therapeutics, Inc.
$221.38+0.00%
XENEXenon Pharmaceuticals Inc.
$65.42-1.15%
KNSAKiniksa Pharmaceuticals International, plc
$63.05+0.98%
LEGNLegend Biotech Corporation
$23.53+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
NOKNokia
$9.73-0.05%
INTCIntel
$100.23-0.02%
AALAmerican Airlines Group
$13.56-0.08%

Questions About SRRK

What is the current price of Scholar Rock?

Scholar Rock is trading at $49.48 per share.

What is the 52-week range for Scholar Rock?

Over the past 52 weeks, Scholar Rock has traded between $27.07 and $58.49.

How much debt does Scholar Rock have?

As of the most recent reporting period, Scholar Rock reported total debt of $205.67M.

How much cash does Scholar Rock have on hand?

Scholar Rock reported $430.54M in cash and cash equivalents in its most recent financial results.

What is Scholar Rock’s dividend yield?

Scholar Rock does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services